期刊
NATURE REVIEWS CARDIOLOGY
卷 8, 期 10, 页码 592-600出版社
NATURE RESEARCH
DOI: 10.1038/nrcardio.2011.128
关键词
-
Antiplatelet therapies have reduced the frequency of adverse events associated with plaque rupture in several clinical situations. These therapies include established antiplatelet agents (such as aspirin, clopidogrel, or glycoprotein IIb/IIIa inhibitors) as well as new agents (such as prasugrel and ticagrelor). In this Review, we address the most important adverse events of antiplatelet therapy, including hemorrhage, hematologic reactions, and dyspnea. We discuss strategies to reduce the incidence of complications and outline potential methods to manage adverse reactions. Interactions between antiplatelet agents and other drugs-such as proton-pump inhibitors, calcium-channel blockers, statins, warfarin, or NSAIDs-are also addressed, as well as specific issues relating to the use of antiplatelet therapies in elderly patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据